Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ondansetron in OCD and Tic Disorders
NCT03239210Phase 4Completed
- Sponsor
- NYU Langone Health
- Start
- Jun 2017
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in obsessive compulsive disorder (OCD), tic disorder and Tourette syndrome (TS) comparing Ondansetron with Placebo (2 arms). Primary endpoints: Change in Brain Activation - Insula Cortex at Week 4 and Change in Brain Activation - Somatosensory Cortex at Week 4. Started Jun 2017; status: completed.
02
Drugs
ondansetron
03
Conditions
obsessive compulsive disorder (OCD)tic disorderTourette syndrome (TS)
Beyond the preview
Go deeper on NCT03239210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03239210.